Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. (Q35570274)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

main subject

phase I clinical trial

0 references

author

Louis B Nabors

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Myrna Rosenfeld

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

J G Supko

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

M Chamberlain

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S Phuphanich

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

T Batchelor

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S Desideri

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

X Ye

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

J Wright

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S Gujar

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S A Grossman

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

27 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

1324-1330

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

13 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Sorafenib in advanced clear-cell renal-cell carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Sorafenib for the treatment of advanced renal cell carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Interactions between antiepileptic and chemotherapeutic drugs

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Distress and quality of life in primary high-grade brain tumor patients.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Sorafenib in advanced hepatocellular carcinoma

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

BAY 43-9006: preclinical data

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3223097

Preparation of mean drug concentration--time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21954442

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21954442

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21954442

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/NEUONC/NOR145

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21954442%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference